Salarius Pharmaceuticals cuts half of workforce despite positive clinical developments


Despite positive feedback from the FDA, Salarius Pharmaceuticals cut half of its workforce in early August. The company also is exploring strategic alternatives, including the possibility of a merger, acquisition or more.

Previous Sarasota cardiac data management company gets backing from NY private equity firm
Next State funding for Eastie health center aids influx of migrants